NGS live webinar: an innovative large cohort study for breast cancer risk – sequencing 60,000 samples

QIAseq_Targeted_DNApanels_700x233

Next-generation sequencing (NGS) is being utilized for numerous new and exciting applications. One application includes analyzing the genetic variants of targeted genes that are associated with cancer development to assess cancer risk.

Targeted DNA sequencing with a focused set of genes is a powerful and widely used approach to detect low-frequency variants. However, researchers using this approach still face various challenges, such as PCR duplication during amplification steps, sequencing errors or artifacts that can limit variant calling accuracy.

QIAGEN has developed a new platform – the QIAseq Targeted DNA Panels – to overcome these challenges. This new platform can increase your confidence in detecting true DNA variants and can help you gain insight from your precious samples. The QIAseq Targeted DNA Panels are based on a novel digital sequencing approach using random molecular barcodes. Each unique DNA molecule is barcoded before any amplification takes place, so unique DNA molecules can be distinguished from PCR duplicates or errors. This feature opens the door for you to confidently detect low-frequency variants. In addition, the new approach uses proprietary chemistry that overcomes the challenges of sequencing GC-rich genomic regions, delivering an unmatched high degree of uniformity.

Join us for a live webinar to learn how this innovative digital sequencing system has been tested to sequence 60,000 samples in an innovative large cohort study assessing breast cancer risks. Dr. Fergus J. Couch, Professor and Chair of the Division of Experimental Pathology and Laboratory Medicine at the Mayo Clinic, will present the study design of an NCI-funded project, which comprises the sequencing of 60,000 samples to assess the risk of breast cancer through association with targeted genes. The design and scale of the study requires an accurate, robust and high-throughput sequencing method. To meet this stringent study requirement, the investigators are using QIAGEN’s digital DNA sequencing approach – the QIAseq Targeted DNA Panels.

Webinar information:

Title: Sequencing 60,000 Samples: An Innovative Large Cohort Study for Breast Cancer Risk

Date: Thursday, July 21, 2016

Time: 1:00 pm Eastern Daylight Time (New York, GMT-04:00)

Speakers:
• Fergus J. Couch, Ph.D., Professor and Chair Division of Experimental Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota
• Raed Samara, Ph.D., Global Product Manager, NGS Solutions, QIAGEN

 

Update:

Watch the webinar recording and learn more about the study design, methodology and the exceptional performance of this digital DNA sequencing approach!

 

The applications presented here are for research use only. Not for use in diagnostic procedures.

Wei Cao, Ph.D.

Senior Global Marketing Manager, Translational Sciences

Dr. Wei Cao joined QIAGEN in 2010 and currently leads the webinar program, presenting various topics on advanced techniques in biomedical research. She received her Ph.D. from Peking University in China in 2010, and conducted postdoctoral research at Weill Cornell Medical College in New York City. Before joining QIAGEN, Dr. Cao worked as a senior scientist in R&D in pharmaceutical and biotech, focusing on HIV, HCV and cancer drug discovery and development.

Your email address will not be published. Required fields are marked *